Tom, all I can tell you is the only way HOTI makes its revenue is by storing UCBs and other stems. If we are infact somehow connected to them our storage numbers increase as they have predicted their revenue stream picture will increase by providing the cure. There projection numbers are 2010 - 2015 and none are flat.
1)The market for heart regeneration procedures is approximately $60 million and is expected to exceed $100 million per year by 2013.
This translates to a market for Regenetech’s expansion technology for research and treatment of $6 million increasing to $10 million by 2013.
Use of Regenetech’s cells for heart regeneration would add less than 1% of cost to the total process.
((Where are they storing the heart cells?))
The market for pancreas regeneration research and treatment procedures (diabetes “cure”) is estimated to be $1 million currently and is expected to exceed $100 million per year by 2013.
Use of Regenetech’s cells in pancreas regeneration will substantially reduce the cost of diabetes care and treatment. The market for all organ repair or regeneration research and therapies is expected to exceed $50 billion per year by 2013.
((Where are they storing the pancreatic cells?))
Within this market, the estimated cost of cell expansion research and treatment services is assumed to be $10,000,000 currently and is expected to reach $2 billion by 2013.
Assuming a reasonable royalty of 5% of the total costs of cell expansion services, the total market potential for the licensing of Regenetech’s technology could be as large as $100 million per year by 2013. Regenetech believes it can capture at least 10% of this market through its research and licensing.
((Is Corcell able to capture a piece or is it able to do so based on its "Know-How" able to ride this projected $100 million wave?))
THE MARKET FOR DIABETES
According to the International Diabetes Federation diabetes is one of the world’s most important causes of expenditure, mortality, disability and lost economic growth.
Global health expenditures to treat and prevent diabetes and its complications total at least US $232 billion in 2007. By 2025, this number will exceed US $302 billion.
The world suffers huge losses in the form of foregone economic growth as a result of diabetes. Lost economic growth may be a relatively greater problem in poorer countries. Between 2005 and 2015, the World Health Organization (WHO) predicts net losses in national income from diabetes and cardiovascular disease of some $557 billion in China, $303 billion in the Russian Federation, $336 billion in India, $49 billion in Brazil and $2 billion in the United Republic of Tanzania (2005 ID).
If Regenetech captures only 2% of the market, it could have an income of US $4.64 billion in 2010 or very shortly thereafter and over US $6 billion by 2025. Since economic loss will be offset by Regenetech’s nominal treatment cost, Regenetech’s profit will be essentially the same as health expenditure cost.
((These are the hospitals projections of a certain demand and they all point north. To make any of this work it still goes back to what HOTI said at the beginning: STEM CELL EXPANSION FACILITIES We are planning to develop state-of-the-art Stem Cell Expansion Facilities throughout the world. You can't do any of this w/o those. Could CBAI be one?))
AI
Market Data 
Markets 
